Filter by:
Cardiovascular
December 2024
Global CVCT Forum
Hypertrophic Cardiomyopathies – New Challenges for Future Trials
Cardiovascular
December 2024
Global CVCT Forum
EDG-7500, a First-in-Class Cardiac Sarcomere Modulator, Demonstrates Favorable Tolerability, Safety, and Pharmacokinetics in Healthy Adults and Patients with Hypertrophic Cardiomyopathy
Cardiovascular
November 2024
American Heart Association Scientific Sessions 2024
Chronic administration of EDG-7500, a novel sarcomere modulator, prevents increases in cardiac mass, T1 relaxation time, and left ventricular end diastolic pressure in a Yucatan mini-pig model of genetic non-obstructive hypertrophic cardiomyopathy
Muscular Dystrophy
October 2024
World Muscle Society 2024
Post-Exercise Biomarkers of Muscle Injury are Reduced by Sevasemten, a Fast Myosin Inhibitor, in Adults with Becker Muscular Dystrophy
Muscular Dystrophy
October 2024
World Muscle Society 2024
Protein Biomarkers of Muscle Injury Exhibit Differential Reduction with Subject Age in Adults with Becker Muscular Dystrophy
Muscular Dystrophy
October 2024
World Muscle Society 2024
Clinical Trial Readiness in a Rare and Underserved Disease: Learnings from Community Engagement and the Lived Experience in Becker Muscular Dystrophy (Becker)
Muscular Dystrophy
October 2024
World Muscle Society 2024
Sevasemten, a Fast Myosin Inhibitor, in Adults with Becker Muscular Dystrophy Results in Reduced Muscle Damage Biomarkers and Functional Stabilization
Muscular Dystrophy
October 2024
World Muscle Society 2024
Comparison of short- and long-term proteomic response to the fast skeletal myosin inhibitor, sevasemten (EDG-5506), in Becker muscular dystrophy (BMD)
Muscular Dystrophy
October 2024
World Muscle Society 2024
